Journal of Medical Economics
Volume 26, 2023 - Issue 1
Open access
872
Views
0
CrossRef citations to date
0
Altmetric
Genetic Disease
Re: Response letter to Sanofi’s communication related to “the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States”
Sepehr Farahbakhshiana US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USACorrespondence[email protected]
, Timothy J. Inocenciob Modeling and Meta-analysis, OPEN Health, Bethesda, MD, USA
, Gregory Poormanb Modeling and Meta-analysis, OPEN Health, Bethesda, MD, USA
, Ekaterina Wrighta US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA
, Ravi Ramesh Pathaka US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA
& Michael Bullanoa US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USAhttps://orcid.org/0000-0002-9961-4576
Pages 581-583
|
Received 28 Mar 2023, Accepted 29 Mar 2023, Published online: 17 Apr 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.